|
MechanismEGFR L861Q mutation antagonists [+2] |
|
|
|
|
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 4IIT A randomized, double-blind, placebo-controlled, multi-center clinical trial of Pushen Capsules in the treatment of ischemic stroke
A multicenter, open-label phase IIb clinical study: evaluating the efficacy and safety of sutertinib maleate capsules in patients with locally advanced or metastatic non-small cell lung cancer (Non-resistant rare EGFR mutations only, including L861Q, G719X and/or S768I)
A single-center, randomized, open, 2-sequence, 2-phase clinical study to evaluate the effect of a high-fat diet on the pharmacokinetics of a single oral sutetinib maleate capsule in healthy subjects
100 Clinical Results associated with Suzhong Pharma Group Co. Ltd.
0 Patents (Medical) associated with Suzhong Pharma Group Co. Ltd.
100 Deals associated with Suzhong Pharma Group Co. Ltd.
100 Translational Medicine associated with Suzhong Pharma Group Co. Ltd.